verapamil has been researched along with Hyperplasia in 14 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
Hyperplasia: An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Verapamil is a useful drug with therapeutic targeting on GCH and a potential way to limit mucous production and improve bronchial inflammation." | 7.78 | Effect of verapamil on bronchial goblet cells of asthma: an experimental study on sensitized animals. ( Ghafarzadegan, K; Hadi, R; Khakzad, MR; Meshkat, M; Mirsadraee, M; Mohammadpour, A; Saghari, M, 2012) |
| "The current study investigated the effect of verapamil on the development of intimal hyperplasia (IH) using a sheep model." | 7.70 | Verapamil reduces intimal hyperplasia in a sheep carotid artery patch graft model. ( Ao, PY; Fletcher, JP; Hawthorne, WJ; Vicaretti, M, 2000) |
| "This report concerns a patient with ischemic heart disease, who developed hyperplastic gingivitis with verapamil." | 7.67 | Hyperplastic gingivitis during diltiazem therapy. ( Giustiniani, S; Marieni, M; Robustelli della Cuna, F, 1987) |
| "We observed gingival hyperplasia, similar clinically to the hyperplasia caused by diphenylhydantoin during the last 11 months in two patients treated by verapamil, suffering from angina pectoris pains." | 7.67 | [Hypertrophic gingivitis caused by verapamil]. ( Cucchi, G; Giustiniani, S; Robustelli, F, 1985) |
| "Paclitaxel has been shown to inhibit vascular smooth muscle cell migration and proliferation contributing to neointimal formation." | 5.32 | Novel oral formulation of paclitaxel inhibits neointimal hyperplasia in a rat carotid artery injury model. ( Cho, MC; Kim, DW; Kim, MS; Kim, YG; Kwon, JS; Lee, GS; Youn, TJ, 2004) |
| "Verapamil treatment significantly reduces intimal hyperplasia in experimental vein grafts and inhibits smooth muscle cell proliferation in culture." | 5.28 | Reduction of intimal hyperplasia and enhanced reactivity of experimental vein bypass grafts with verapamil treatment. ( Cross, KS; el-Sanadiki, MN; Hagen, PO; McCann, RL; Mikat, E; Murray, JJ; Schuman, RW, 1990) |
| " To investigate the nature and the origin of the antihyperplastic effects, we tested topical pretreatment with pindolol, heptaminol, ATRA or verapamil against Balb/c mouse ear skin hyperplasia that was induced by TPA." | 3.83 | NO-dependent attenuation of TPA-induced immunoinflammatory skin changes in Balb/c mice by pindolol, heptaminol or ATRA, but not by verapamil. ( Cheon, SA; Chung, JF; Joo, MY; Kim, B; Kim, KH; Lee, SJ; Park, SH; Park, TJ; Seo, ES; Sood, AK; Yang, JS; Yoon, CJ, 2016) |
| "Verapamil is a useful drug with therapeutic targeting on GCH and a potential way to limit mucous production and improve bronchial inflammation." | 3.78 | Effect of verapamil on bronchial goblet cells of asthma: an experimental study on sensitized animals. ( Ghafarzadegan, K; Hadi, R; Khakzad, MR; Meshkat, M; Mirsadraee, M; Mohammadpour, A; Saghari, M, 2012) |
| "The potential of the calcium channel antagonist verapamil to cause apoptosis (programmed cell death) is of considerable importance in arterial injury where the loss of smooth muscle cells may contribute to a reduction in intimal hyperplasia development." | 3.71 | Calcium channel antagonist verapamil inhibits neointimal formation and enhances apoptosis in a vascular graft model. ( Angeli, GL; Fletcher, JP; Hawthorne, WJ; Huang, P; Medbury, HJ; Peng, A, 2001) |
| "This report concerns a patient with ischemic heart disease, who developed hyperplastic gingivitis with verapamil." | 3.67 | Hyperplastic gingivitis during diltiazem therapy. ( Giustiniani, S; Marieni, M; Robustelli della Cuna, F, 1987) |
| "We observed gingival hyperplasia, similar clinically to the hyperplasia caused by diphenylhydantoin during the last 11 months in two patients treated by verapamil, suffering from angina pectoris pains." | 3.67 | [Hypertrophic gingivitis caused by verapamil]. ( Cucchi, G; Giustiniani, S; Robustelli, F, 1985) |
| "Paclitaxel has been shown to inhibit vascular smooth muscle cell migration and proliferation contributing to neointimal formation." | 1.32 | Novel oral formulation of paclitaxel inhibits neointimal hyperplasia in a rat carotid artery injury model. ( Cho, MC; Kim, DW; Kim, MS; Kim, YG; Kwon, JS; Lee, GS; Youn, TJ, 2004) |
| "Verapamil treatment significantly reduces intimal hyperplasia in experimental vein grafts and inhibits smooth muscle cell proliferation in culture." | 1.28 | Reduction of intimal hyperplasia and enhanced reactivity of experimental vein bypass grafts with verapamil treatment. ( Cross, KS; el-Sanadiki, MN; Hagen, PO; McCann, RL; Mikat, E; Murray, JJ; Schuman, RW, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (14.29) | 18.7374 |
| 1990's | 6 (42.86) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chung, JF | 1 |
| Yoon, CJ | 1 |
| Cheon, SA | 1 |
| Seo, ES | 1 |
| Park, SH | 1 |
| Yang, JS | 1 |
| Kim, B | 1 |
| Joo, MY | 1 |
| Park, TJ | 1 |
| Kim, KH | 1 |
| Sood, AK | 1 |
| Lee, SJ | 1 |
| Khakzad, MR | 1 |
| Mirsadraee, M | 1 |
| Mohammadpour, A | 1 |
| Ghafarzadegan, K | 1 |
| Hadi, R | 1 |
| Saghari, M | 1 |
| Meshkat, M | 1 |
| Denda, M | 1 |
| Fuziwara, S | 1 |
| Inoue, K | 1 |
| Kim, DW | 1 |
| Kwon, JS | 1 |
| Kim, YG | 1 |
| Kim, MS | 1 |
| Lee, GS | 1 |
| Youn, TJ | 1 |
| Cho, MC | 1 |
| Mehra, MR | 1 |
| Ventura, HO | 1 |
| Smart, FW | 1 |
| Collins, TJ | 1 |
| Ramee, SR | 1 |
| Stapleton, DD | 1 |
| Battalora, MS | 1 |
| Johnston, DA | 1 |
| DiGiovanni, J | 1 |
| Liu, N | 1 |
| Ren, X | 1 |
| Cen, L | 1 |
| Ao, PY | 1 |
| Hawthorne, WJ | 2 |
| Vicaretti, M | 1 |
| Fletcher, JP | 2 |
| Huang, P | 1 |
| Peng, A | 1 |
| Angeli, GL | 1 |
| Medbury, HJ | 1 |
| Kaesemeyer, WH | 1 |
| Prisant, LM | 1 |
| Carr, AA | 1 |
| Paniszyn, CC | 1 |
| el-Sanadiki, MN | 1 |
| Cross, KS | 1 |
| Murray, JJ | 1 |
| Schuman, RW | 1 |
| Mikat, E | 1 |
| McCann, RL | 1 |
| Hagen, PO | 1 |
| Giustiniani, S | 2 |
| Robustelli della Cuna, F | 1 |
| Marieni, M | 1 |
| Cucchi, G | 1 |
| Robustelli, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase Ib/II Clinical Trial of Topical Verapamil Hydrochloride for Chronic Rhinosinusitis With Nasal Polyps[NCT03102190] | Phase 1 | 6 participants (Actual) | Interventional | 2017-06-05 | Terminated (stopped due to Phase II funding not available) | ||
| Randomized Double Blind Placebo Controlled Trial of Verapamil in Chronic Rhinosinusitis[NCT02454608] | 29 participants (Actual) | Interventional | 2015-05-31 | Terminated (stopped due to Evidence that the dose is insufficient.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Dose Limiting Toxicity will be defined as a development of 2nd or 3rd degree heart block as measured by an EKG. (Phase Ib primary outcome) (NCT03102190)
Timeframe: 1-8 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Phase Ib | 0 |
(NCT02454608)
Timeframe: Mean change between baseline and week 8 measurements
| Intervention | mmHg (Mean) |
|---|---|
| Treatment | -0.6 |
| Control | 1 |
(NCT02454608)
Timeframe: Mean change between baseline and week 8 measurements.
| Intervention | beats per minute (Mean) |
|---|---|
| Treatment | -1.4 |
| Control | 4 |
Minimum Score: 0 Maximum Score: 12 Higher value represents worse outcome. (NCT02454608)
Timeframe: baseline to week 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Treatment | -1.3 |
| Control | -0.25 |
Minimum Score: 0 Maximum Score: 24 Higher value represents worse outcome. (NCT02454608)
Timeframe: Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Treatment | 12.5 |
| Control | 17.7 |
Minimum Score: 0 Maximum Score: 100 A higher score indicates a worse outcome. (NCT02454608)
Timeframe: baseline to week 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Treatment | -44.03 |
| Control | -6.07 |
Minimum Score: 0 Maximum Score: 110 A higher score indicates a worse outcome (NCT02454608)
Timeframe: baseline to week 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Treatment | -27.3 |
| Control | 0.4 |
(NCT02454608)
Timeframe: Mean change between baseline and week 8 measurements
| Intervention | mmHg (Mean) |
|---|---|
| Treatment | -4.5 |
| Control | -6.6 |
Minimum Score: 0 Maximum Score: 100 A higher score indicates a worse outcome. (NCT02454608)
Timeframe: baseline to week 56
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Medicine Completers, baseline | Medicine Completers, week 56 | Surgical Completers, baseline | Surgical Completers, week 12 | |
| Open Label | 64.3 | 35.0 | 90.0 | 16.7 |
Minimum Score: 0 Maximum Score: 110 A higher score indicates a worse outcome (NCT02454608)
Timeframe: baseline to week 56
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Medicine Completers, baseline | Medicine Completers, week 56 | Surgical Completers, baseline | Surgical Completers, week 12 | |
| Open Label | 31.8 | 24.14 | 72.00 | 8.00 |
14 other studies available for verapamil and Hyperplasia
| Article | Year |
|---|---|
NO-dependent attenuation of TPA-induced immunoinflammatory skin changes in Balb/c mice by pindolol, heptaminol or ATRA, but not by verapamil.
Topics: Animals; Female; Fibrosis; Heptaminol; Hyperplasia; Killer Cells, Natural; Mice; Mice, Inbred BALB C | 2016 |
Effect of verapamil on bronchial goblet cells of asthma: an experimental study on sensitized animals.
Topics: Animals; Asthma; Bronchi; Bronchoalveolar Lavage Fluid; Calcium Channel Blockers; Disease Models, An | 2012 |
Effect of verapamil on bronchial goblet cells of asthma: an experimental study on sensitized animals.
Topics: Animals; Asthma; Bronchi; Bronchoalveolar Lavage Fluid; Calcium Channel Blockers; Disease Models, An | 2012 |
Effect of verapamil on bronchial goblet cells of asthma: an experimental study on sensitized animals.
Topics: Animals; Asthma; Bronchi; Bronchoalveolar Lavage Fluid; Calcium Channel Blockers; Disease Models, An | 2012 |
Effect of verapamil on bronchial goblet cells of asthma: an experimental study on sensitized animals.
Topics: Animals; Asthma; Bronchi; Bronchoalveolar Lavage Fluid; Calcium Channel Blockers; Disease Models, An | 2012 |
Beta2-adrenergic receptor antagonist accelerates skin barrier recovery and reduces epidermal hyperplasia induced by barrier disruption.
Topics: Adrenergic beta-2 Receptor Antagonists; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Alpre | 2003 |
Novel oral formulation of paclitaxel inhibits neointimal hyperplasia in a rat carotid artery injury model.
Topics: Administration, Oral; alpha-Tocopherol; Animals; ATP Binding Cassette Transporter, Subfamily B, Memb | 2004 |
An intravascular ultrasound study of the influence of angiotensin-converting enzyme inhibitors and calcium entry blockers on the development of cardiac allograft vasculopathy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Captopril; Coronary Disease; Dil | 1995 |
The effects of calcium antagonists on anthrone skin tumor promotion and promoter-related effects in SENCAR mice.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Anthracenes; Calcium; Calcium Channel Blockers; Carcinoge | 1995 |
[The disturbance of calcium homeostasis in vascular smooth muscle proliferation after balloon denudation].
Topics: Animals; Biological Transport, Active; Calcium; Calcium Channel Blockers; Homeostasis; Hyperplasia; | 1996 |
Verapamil reduces intimal hyperplasia in a sheep carotid artery patch graft model.
Topics: Animals; Calcium Channel Blockers; Carotid Arteries; Hyperplasia; Polyethylene Terephthalates; Prost | 2000 |
Calcium channel antagonist verapamil inhibits neointimal formation and enhances apoptosis in a vascular graft model.
Topics: Analysis of Variance; Animals; Apoptosis; Calcium Channel Blockers; Carotid Artery, Common; Disease | 2001 |
Verapamil and nifedipine in combination for the treatment of hypertrophy heart disease.
Topics: Adrenal Gland Diseases; Blood Pressure; Cardiovascular Diseases; Drug Therapy, Combination; Humans; | 1991 |
Reduction of intimal hyperplasia and enhanced reactivity of experimental vein bypass grafts with verapamil treatment.
Topics: Animals; Endothelium, Vascular; Hyperplasia; Veins; Verapamil | 1991 |
Reduction of intimal hyperplasia and enhanced reactivity of experimental vein bypass grafts with verapamil treatment.
Topics: Animals; Blood Pressure; Carotid Arteries; Cholesterol; DNA; Dose-Response Relationship, Drug; Hyper | 1990 |
Hyperplastic gingivitis during diltiazem therapy.
Topics: Calcium Channel Blockers; Diltiazem; Gingiva; Gingivitis; Humans; Hyperplasia; Male; Middle Aged; Ve | 1987 |
[Hypertrophic gingivitis caused by verapamil].
Topics: Angina Pectoris; Gingivitis; Humans; Hyperplasia; Male; Middle Aged; Phenytoin; Verapamil | 1985 |